Neon Therapeutics, Inc. (NTGN)
| Market Cap | 88.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 28.96M |
| EPS (ttm) | -2.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6, 2020 |
| Last Price | $3.07 |
| Previous Close | $3.07 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 2.92 - 3.09 |
| Day's Volume | 3,609,767 |
| 52-Week Range | 0.88 - 6.15 |
News
Phase 1 Clinical Trial of Personal Neoantigen-Targeted T Cell Therapy Expected to Initiate in Third Quarter 2020 Phase 1 Clinical Trial of Personal Neoantigen-Targeted T Cell Therapy Expected ...
BioNTech's Acquisition Of Neon Highlights Potential Use Of Neoantigens For Cancer Treatment
As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.
Neon Therapeutics (NTGN ) news for Thursday about a $67.00 million deal with BioNTech (BNTX) has NTGN stock soaring on Thursday. The post Neon Therapeutics News: NTGN Stock Rockets 38% on BioN...
Neon Therapeutics Inc. (NASDAQ: NTGN) shares shot up on Thursday after the firm announced that it will be acquired by BioNTech SE (NASDAQ: BNTX).
MAINZ, Germany and CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have e...
Study of NEO-PTC-01 in metastatic melanoma patients expected to initiate in first half of 2020 Study of NEO-PTC-01 in metastatic melanoma patients expected to initiate in first half of 2020
Shares of Neon Therapeutics NTGN, -4.03% were up 19% in after-hours trading Wednesday after the company announced a corporate restructuring that includes cutting 24% of its workforce.
Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors
Updated Results from NT-001 Trial of NEO-PV-01 Demonstrate Prolonged Progression-Free and Overall Survival vs. Historical Benchmark Data
Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods
Neon Therapeutics achieved positive results using NEO-PV-01 when combined with OPDIVO in patients with a few types of cancer.
Neon Therapeutics (NASDAQ: NTGN) shares are trading higher after the company announced its personal neoantigen vaccine study demonstrated prolonged progression-free survival in advanced or met...
About NTGN
Neon Therapeutics, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial for the treatment of advanced or metastatic non-small cell lung cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of hormone-receptor-positive breast cancer, as well as NEO-STC-01, a neoantigen adoptive T cell therapy for the treatm... [Read more...]
| Industry Biotechnology | IPO Date Jun 27, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol NTGN |